Glioblastoma
MONDO:0018177The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)
Also known as: GBM, GBM (glioblastoma), WHO grade IV glioma, glioblastoma, glioblastoma (disease), glioblastoma multiforme, glioblastoma multiforme (disease), grade IV astrocytic neoplasm
3412 clinical trials for this condition and its sub-types, 638 tagged with Glioblastoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Glioblastoma
-
Brain glioblastoma 24 trials · 87 incl. sub-types
3 sub-types
- Gliosarcoma 65 trials
- Giant cell glioblastoma 7 trials
- Brain stem glioblastoma 1 trial
-
IDH-wildtype glioblastoma 83 trials
-
Adult glioblastoma 25 trials
1 sub-type
- Adult spinal cord glioblastoma 0 trials
-
Classical glioblastoma 3 trials
-
Mesenchymal glioblastoma 0 trials
-
Neural glioblastoma 0 trials
-
Proneural glioblastoma 0 trials
-
Brain cancer vaccine trial halted: what we know
Vaccine Stopped earlyThis study tested a vaccine called VBI-1901 in 70 people with recurrent glioblastoma, an aggressive brain cancer. The goal was to find a safe dose and see if the vaccine could boost the immune system against the tumor. The trial was terminated early, so results are limited.
Phase 1/2 • Sponsor: VBI Vaccines Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:30 UTC
-
Engineered immune cells take aim at deadly brain tumors
Disease control Stopped earlyThis early-phase trial is testing a new treatment called CHM-1101 for people with a type of brain cancer (glioblastoma) that has come back or is getting worse. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack tumor cells. The …
Phase 1 • Sponsor: Chimeric Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Gene therapy takes on deadly brain tumor
Disease control Stopped earlyThis study tests a new treatment called Temferon for people with glioblastoma, a fast-growing brain cancer. The therapy uses a patient's own blood stem cells, modified to deliver interferon directly to the tumor. Up to 27 patients with a specific genetic marker (unmethylated MGMT…
Phase 1/2 • Sponsor: Genenta Science • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New light therapy for brain cancer shows promise in early trial
Disease control Stopped earlyThis trial tested a light-activated drug called PD L 506 (5-aminolevulinic acid) in 17 adults with a type of aggressive brain tumor called glioblastoma that could not be fully removed by surgery. The drug is given by mouth and then activated by a laser inserted into the brain to …
Phase 2 • Sponsor: photonamic GmbH & Co. KG • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New way to deliver chemo directly to brain tumors tested in small study
Disease control Stopped earlyThis early-phase trial tested a single dose of the cancer drug temsirolimus, given directly into the brain's blood supply, for people with recurrent high-grade glioma (a fast-growing brain tumor). Only 5 participants were enrolled, and the study was terminated early. The main goa…
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Hormone therapy explored for aggressive brain tumor
Disease control Stopped earlyThis early-phase study tested whether natural progesterone, a hormone normally involved in pregnancy, could help control recurrent glioblastoma (a fast-growing brain cancer). Four adults whose cancer had returned after standard treatments received daily progesterone injections un…
Early phase 1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental drug RMC-5552 tested in recurrent glioblastoma – early trial ends
Disease control Stopped earlyThis early-phase trial tested the drug RMC-5552 in 7 adults with glioblastoma that had returned after standard treatment. The drug works by blocking a protein called mTOR, which may help stop cancer cells from growing. The study aimed to find the safest dose and check for side ef…
Phase 1 • Sponsor: Nicholas Butowski • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New radiation technique tested for aggressive brain cancer
Disease control Stopped earlyThis phase 3 trial tested two types of radiation therapy for glioblastoma, a fast-growing brain tumor. One group received standard 3D radiation, while the other got a more precise intensity-modulated radiation guided by MRI scans. Both groups also took the chemotherapy drug temoz…
Phase 3 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental cancer drug TNG908 tested in patients with rare gene deletion
Disease control Stopped earlyThis study tested an experimental oral drug called TNG908 in people with advanced solid tumors that have lost a gene called MTAP. The goal was to see if the drug is safe and can shrink tumors. The study was planned for up to 192 participants but was terminated early, so results a…
Phase 1/2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental combo therapy for brain cancer shows promise in early trial
Disease control Stopped earlyThis study tested a special type of radiation (pulse reduced dose rate) combined with the drug bevacizumab in 49 people with recurrent high-grade gliomas (brain tumors). The goal was to see if this combination could help patients live longer. Participants received radiation over …
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Brain tumor drug trial halted before results
Disease control Stopped earlyThis study tested the drug cabozantinib in 19 people with a severe type of brain tumor (grade IV astrocytic tumors) that had come back after initial treatment. The goal was to see if the drug could shrink tumors or slow progression. However, the company stopped the trial early fo…
Phase 2 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental brain tumor combo shows promise but trial halted early
Disease control Stopped earlyThis study tested a new drug called zotiraciclib (TG02) combined with the standard chemotherapy temozolomide in adults with recurrent anaplastic astrocytoma or glioblastoma. The goal was to find the safest dose and see if the combination worked better than temozolomide alone. The…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Targeted drug pemigatinib tested in brain tumors with specific genetic markers
Disease control Stopped earlyThis phase 2 trial tested the drug pemigatinib in people with recurrent glioblastoma or other brain tumors that have specific changes in FGFR1-3 genes. Participants took a daily tablet for two weeks followed by one week off. The study aimed to see if the drug could shrink tumors,…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Experimental radioactive therapy targets Hard-to-Treat cancers
Disease control Stopped earlyThis early-stage study tested a radioactive drug called 177Lu-FF58 in 24 people with advanced pancreatic, gastroesophageal, or brain cancer. The drug seeks out and attaches to specific proteins on cancer cells to deliver radiation directly. The main goals were to check safety, fi…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental drug aims to supercharge radiation against glioblastoma
Disease control Stopped earlyThis Phase 2 trial tested a drug called ropidoxuridine, taken as a pill, to see if it could make radiation therapy more effective for people with a newly diagnosed, aggressive type of brain cancer (glioblastoma). The study enrolled 30 patients with a specific genetic marker (unme…
Phase 2 • Sponsor: Shuttle Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental drug navtemadlin tested for glioblastoma
Disease control Stopped earlyThis early-phase trial tested the drug navtemadlin in 32 adults with glioblastoma, a type of brain cancer. The study aimed to find the best dose and check side effects, both for newly diagnosed and recurrent cases. The trial was terminated early, so results are limited.
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental Pre-Surgery treatment for brain cancer shows early hurdles
Disease control Stopped earlyThis study looked at whether giving chemotherapy and radiation before surgery could help control glioblastoma, a fast-growing brain tumor. Only 2 people enrolled before the study was stopped. The goal was to see if this approach was safe and could delay tumor regrowth.
Phase 2 • Sponsor: Geisinger Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had specific genetic changes (EGFR or HER2). The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped e…
Phase 1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Brain cancer drug trial halted after just two patients
Disease control Stopped earlyThis study tested a new drug called VAL-083 in people with glioblastoma, an aggressive brain cancer that had returned after standard treatments. The trial aimed to see if VAL-083 could help patients live longer. However, the study was stopped early after only 2 people enrolled, s…
Phase 3 • Sponsor: DelMar Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:46 UTC
-
New imaging agent aims to spot Hard-to-Find cancers
Diagnosis Stopped earlyThis early-phase trial tested a radioactive imaging agent called 68Ga-FF58 in 14 adults with certain advanced solid tumors (glioblastoma, brain metastases from breast cancer, gastroesophageal cancer, or pancreatic cancer). The goal was to see if the agent could help detect these …
Early phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
New MRI technique aims to solve brain tumor treatment mystery
Diagnosis Stopped earlyThis pilot study tested whether a special MRI using ferumoxytol (an iron-based contrast agent) can better distinguish true tumor growth from treatment-related inflammation (pseudoprogression) in people with glioblastoma receiving the immunotherapy drug pembrolizumab. The study en…
Phase 2 • Sponsor: OHSU Knight Cancer Institute • Aim: Diagnosis
Last updated Jun 26, 2026 15:10 UTC
-
Wakefulness drug shows promise for brain tumor fatigue, but study stalls
Symptom relief Stopped earlyThis study tested a drug called solriamfetol to see if it could safely help people with brain tumors (gliomas) feel more awake, think clearer, and have a better quality of life. Only 2 people enrolled before the study was stopped early. The main goal was to check for serious side…
Phase 2 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
CBD anxiety trial for brain cancer patients ends early
Symptom relief Stopped earlyThis study aimed to see if a high-CBD hemp product could reduce anxiety and improve quality of life in people newly diagnosed with glioblastoma, a serious brain tumor. The trial planned to compare the CBD product to a placebo over 8 weeks, but it was stopped early after only 2 pe…
Phase 2 • Sponsor: Mclean Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Spinal tap could replace brain surgery for young tumor patients
Knowledge-focused Stopped earlyThis study looked at whether a liquid biopsy—testing the fluid around the brain and spinal cord—can find tumor DNA in children and young adults with brain tumors. The goal was to see if this safer, non-surgical test could replace risky tissue biopsies for diagnosis and monitoring…
Sponsor: Pediatric Brain Tumor Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Could a common antifungal pill fight brain tumors?
Knowledge-focused Stopped earlyThis early-phase trial tested whether posaconazole, a drug used for fungal infections, can reach brain tumors in high enough amounts to stop cancer cells from dividing. Seven adults with glioblastoma took the drug before surgery, and researchers measured drug levels in their spin…
Early phase 1 • Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Antifungal drug tested against brain cancer — but trial stops early
Knowledge-focused Stopped earlyThis early-phase trial tested whether ketoconazole, a drug normally used for fungal infections, can enter brain tumors in high enough amounts to stop tumor cells from dividing. Only 1 person was enrolled before the study was terminated. The goal was to measure drug levels in the …
Early phase 1 • Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Brain tumor drug penetration study halted early
Knowledge-focused Stopped earlyThis early-phase trial aimed to measure how much of the drug infigratinib reaches brain tumor tissue in people with recurrent high-grade glioma (a type of brain cancer). Only 7 participants were enrolled before the study was terminated. The main goal was to check drug levels in t…
Early phase 1 • Sponsor: Nader Sanai • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Brain tumor study looks at tiny molecule as possible clue
Knowledge-focused Stopped earlyThis study looked at a tiny molecule called microRNA-10b in people with brain tumors called gliomas. Researchers wanted to see if higher levels of this molecule could help predict how the disease might progress or how long patients might live. The study was stopped early, but it …
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:16 UTC